

Samuli Eldfors

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/27056/publications.pdf>

Version: 2024-02-01

74
papers

2,938
citations

346980

22
h-index

299063

42
g-index

77
all docs

77
docs citations

77
times ranked

5933
citing authors

#	ARTICLE	IF	CITATIONS
1	Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2012, 366, 1905-1913.	13.9	681
2	Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2013, 3, 1416-1429.	7.7	334
3	Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. <i>Blood</i> , 2013, 121, 4541-4550.	0.6	252
4	Comparison of solution-based exome capture methods for next generation sequencing. <i>Genome Biology</i> , 2011, 12, R94.	13.9	237
5	Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3. <i>Blood</i> , 2015, 125, 639-648.	0.6	229
6	Aggressive natural killer-cell leukemia—mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. <i>Nature Communications</i> , 2018, 9, 1567.	5.8	107
7	Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2014, 28, 1738-1742.	3.3	90
8	High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. <i>Blood</i> , 2016, 128, 2465-2468.	0.6	86
9	Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis. <i>Nature Communications</i> , 2017, 8, 15869.	5.8	83
10	Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. <i>Leukemia</i> , 2018, 32, 774-787.	3.3	75
11	Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 319-327.	0.9	74
12	Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2022, 12, 388-401.	7.7	73
13	Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia. <i>Leukemia</i> , 2016, 30, 1204-1208.	3.3	62
14	HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. <i>Leukemia</i> , 2017, 31, 301-309.	3.3	61
15	Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation. <i>Blood Cancer Journal</i> , 2013, 3, e168-e168.	2.8	56
16	Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML. <i>Leukemia</i> , 2017, 31, 1187-1195.	3.3	44
17	Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia. <i>Leukemia</i> , 2017, 31, 51-57.	3.3	42
18	Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1360-1372.	3.3	40

#	ARTICLE	IF	CITATIONS
19	Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 546-559.	2.5	36
20	Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing. <i>Oncotarget</i> , 2017, 8, 56338-56350.	0.8	35
21	Converging endometrial and ovarian tumorigenesis in Lynch syndrome: Shared origin of synchronous carcinomas. <i>Gynecologic Oncology</i> , 2018, 150, 92-98.	0.6	29
22	Clonal heterogeneity influences drug responsiveness in renal cancer assessed by <i>ex vivo</i> drug testing of multiple patient-derived cancer cells. <i>International Journal of Cancer</i> , 2019, 144, 1356-1366.	2.3	29
23	Epidemiological, clinical and molecular characterization of Lynch-like syndrome: A population-based study. <i>International Journal of Cancer</i> , 2019, 145, 87-98.	2.3	28
24	Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease. <i>Nature Communications</i> , 2020, 11, 2246.	5.8	20
25	Sequencing of Lynch syndrome tumors reveals the importance of epigenetic alterations. <i>Oncotarget</i> , 2017, 8, 108020-108030.	0.8	18
26	Somatic mutations and T-cell clonality in patients with immunodeficiency. <i>Haematologica</i> , 2020, 105, 2757-2768.	1.7	18
27	Novel TBL1XR1, EPHA7 and SLFN12 mutations in a Sezary syndrome patient discovered by whole exome sequencing. <i>Experimental Dermatology</i> , 2014, 23, 366-368.	1.4	12
28	Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer. <i>BMC Cancer</i> , 2016, 16, 378.	1.1	11
29	Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia. <i>Leukemia</i> , 2017, 31, 1048-1058.	3.3	11
30	Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature. <i>Frontiers in Immunology</i> , 2020, 11, 578848.	2.2	11
31	Does breast carcinoma belong to the Lynch syndrome tumor spectrum? " Somatic mutational profiles vs. ovarian and colorectal carcinomas. <i>Oncotarget</i> , 2020, 11, 1244-1256.	0.8	11
32	Molecular Basis of Mismatch Repair Protein Deficiency in Tumors from Lynch Suspected Cases with Negative Germline Test Results. <i>Cancers</i> , 2020, 12, 1853.	1.7	8
33	Recurrent Missense Mutations in the STAT3 Gene in LGL Leukemia Provide Insights to Pathogenetic Mechanisms and Suggest Potential Diagnostic and Therapeutic Applications. <i>Blood</i> , 2011, 118, 936-936.	0.6	6
34	Rad51c- and Trp53-double-mutant mouse model reveals common features of homologous recombination-deficient breast cancers. <i>Oncogene</i> , 2016, 35, 4601-4610.	2.6	5
35	Novel Activating STAT5B Mutations As Drivers Of T-ALL. <i>Blood</i> , 2013, 122, 3863-3863.	0.6	5
36	Abstract 3175: Genomic and transcriptomic data integration in chronic myelomonocytic leukemia reveals a novel fusion gene involving onco-miR-125b-2. , 2012, , .		3

#	ARTICLE	IF	CITATIONS
37	Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma. <i>Blood</i> , 2014, 124, 2046-2046.	0.6	3
38	Predictive Response Biomarkers for BET Inhibitors in AML. <i>Blood</i> , 2018, 132, 2749-2749.	0.6	2
39	Discovery of STAT5b Mutations and Small Subclones of STAT3 Mutations in Large Granular Lymphocytic (LGL) Leukemia. <i>Blood</i> , 2012, 120, 871-871.	0.6	2
40	Abstract 4580: Personalized treatment selection for therapy-resistant AML by integrating ex-vivo drug sensitivity and resistance testing (DSRT) as well as serial genomic, transcriptomic and phosphoproteomic profiling. , 2012, , .		1
41	Abstract 5067: Exome sequencing reveals both DNA sequence and copy number changes in AML: Potential driver changes and mechanisms of drug resistance revealed from serial samples from the same patients. , 2012, , .		1
42	Somatic Mutations in T Cells As Possible Regulators of Immunodeficiency. <i>Blood</i> , 2018, 132, 515-515.	0.6	1
43	Landscape of Mutations in Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 2367-2367.	0.6	1
44	Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles. <i>Blood</i> , 2017, 130, 854-854.	0.6	1
45	High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML. <i>Blood</i> , 2012, 120, 288-288.	0.6	1
46	Abstract 608: Comprehensive drug testing of patient-derived conditionally reprogrammed cells from castration-resistant prostate cancer. , 2016, , .		1
47	Abstract 2378: Responses of AML patients to tailored drug regimens: monitoring cancer subclones by ultra-deep resequencing. , 2016, , .		1
48	Somatic Mutations in CD8+ T Cells in Patients with Chronic Immune Thrombocytopenia Are Associated with Increased Clonality and Cytotoxic Phenotype of CD8+ T Cells. <i>Blood</i> , 2018, 132, 131-131.	0.6	1
49	825 Exome Sequencing of T-LGL Leukemia Patient Revealed ANGPT2 as a Possible Mutational Target. <i>European Journal of Cancer</i> , 2012, 48, S198.	1.3	0
50	A6.02â€¦Somatic mutations in clonally expanded CD8⁺T cells in patients with newly diagnosed rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, A47.2-A48.	0.5	0
51	Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib. <i>Blood</i> , 2011, 118, 2487-2487.	0.6	0
52	Abstract 895: Quantitative drug sensitivity and resistance testing (DSRT) of primary ex vivo AML blasts highlights mTOR and MEK as potential key molecular driver signals of therapeutic significance. , 2012, , .		0
53	Abstract 3188: Development of a cancer pharmacopeia-wideex-vivodrug sensitivity and resistance testing (DSRT) platform for AML: Towards individually optimized therapy and improved understanding of drug resistance patterns. , 2012, , .		0
54	Somatic PTPRT and ANGPT2 Mutations in Large Granulocyte Leukemia. <i>Blood</i> , 2012, 120, 1302-1302.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex Vivo Drug Testing. <i>Blood</i> , 2013, 122, 3828-3828.	0.6	0
56	Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling. <i>Blood</i> , 2013, 122, 482-482.	0.6	0
57	Abstract 982: Analysis of clonal evolution of leukemia in vivo following novel targeted treatments. , 2014, , .		0
58	Identification of Dual PI3K/mTOR and BCL2 Inhibitors for the Treatment of High Risk Multiple Myeloma. <i>Blood</i> , 2014, 124, 646-646.	0.6	0
59	Landscape of Driver Lesions in Multiple Myeloma and Consequences for Targeted Drug Response. <i>Blood</i> , 2014, 124, 3351-3351.	0.6	0
60	Abstract 606: Novel somatic mutations in the DNA-binding and coiled-coil domain of the STAT3 gene in LGL-leukemia. , 2015, , .		0
61	Stratification of Multiple Myeloma Patients Based on Ex Vivo Drug Sensitivity and Identification of New Treatments for Patients with High-Risk Relapsed/Refractory Disease. <i>Blood</i> , 2015, 126, 3006-3006.	0.6	0
62	BCL2-Inhibitors Target a Major Group of Newly-Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo. <i>Blood</i> , 2015, 126, 2462-2462.	0.6	0
63	Exome Sequencing of Aggressive Natural Killer Cell Leukemia and Drug Profiling Highlight Candidate Driver Pathways in Malignant Natural Killer Cells. <i>Blood</i> , 2015, 126, 700-700.	0.6	0
64	Abstract 4679: Acquisition of cytarabine resistance leads to increased glucocorticoid sensitivity in AML. , 2016, , .		0
65	Mutational Landscape of Aggressive Natural Killer Cell Leukemia and Drug Sensitivity Profiling Reveal Therapeutic Options in Natural Killer Cell Malignancies. <i>Blood</i> , 2016, 128, 2921-2921.	0.6	0
66	Novel Mutations in Patients with Blast Crisis or Accelerated Phase Chronic Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1924-1924.	0.6	0
67	Transcriptional Regulatory Landscape of TCF3-PBX1-Positive Leukemia and Novel Targeted Treatments. <i>Blood</i> , 2016, 128, 4077-4077.	0.6	0
68	DNA Damage Repair Pathway Alterations in Multiple Myeloma Predict Poor Prognosis, but Correlate with Sensitivity to IGF1R-PI3K-mTOR and HDAC Inhibitors. <i>Blood</i> , 2016, 128, 198-198.	0.6	0
69	Abstract 424: Landscape of somatic mutations in drug-resistant acute myeloid leukemia. , 2017, , .		0
70	Abstract 410: Identifying ovarian cancer specific targeted drugs using high-throughput drug sensitivity profiles of primary cancer cells. , 2017, , .		0
71	Abstract 5369: Tumorigenesis in Lynch syndrome: Somatic mutation profiles compared to sporadic counterparts. , 2018, , .		0
72	Abstract 3277: Identification of internal tandem duplication within the FLT3 gene from AML patient next-generation sequence data. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
73	Abstract 2199: Establishment and high-throughput drug testing of multiple patient-derived cells from each renal cancer; intratumor heterogeneity of drug response and implications for precision medicine. , 2018, , .		0
74	Abstract 3899: Discovery and clinical implementation of individualized therapies in acute myeloid leukemia based on ex vivo drug sensitivity testing and multi-omics profiling. , 2018, , .		0